The assertions herein are those of the authors and are not to be construed as official or as reflecting the views of the U.S. Food and Drug Administration at large.
Chapter 7. Immunostimulatory CpG Oligodeoxynucleotides as Vaccine Adjuvants†
- Manmohan Singh M. Pharm., Ph.D.
Published Online: 2 NOV 2006
Copyright © 2007 John Wiley & Sons, Inc.
Vaccine Adjuvants and Delivery Systems
How to Cite
Klinman, D. M., Currie, D. and Shirota, H. (2006) Immunostimulatory CpG Oligodeoxynucleotides as Vaccine Adjuvants, in Vaccine Adjuvants and Delivery Systems (ed M. Singh), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470134931.ch7
Novartis Vaccines, Emeryville, California, USA
- Published Online: 2 NOV 2006
- Published Print: 15 JUN 2007
Print ISBN: 9780471739074
Online ISBN: 9780470134931
- immunostimulatory CpG oligodeoxynucleotides;
- CpG ODNs augmenting immune response;
- cell surface receptor and uptake of D-class CpG ODNs
This chapter contains sections titled:
Immunomodulatory Properties of CpG ODNs
CpG ODNs as Vaccine Adjuvants
CpG ODNs Improve the Response to Mucosal Vaccines
CpG ODNs Augment the Immune Response of Immunocompromized Animals
Adjuvant Activity of CpG ODNs in Nonhuman Primates
Human Clinical Experience
CpG ODN Safety